CARGO Therapeutics has said it plans to offer around 18.8 million shares in the latest bid by a biotech to list on the Nasdaq, amid a desultory year for initial public off
Genetic medicine specialist Lexeo Therapeutics is the latest biotech to line up an initial public offering (IPO), aiming to raise around $100 million from the transaction.
In the ever-evolving landscape of the biotechnology sector, the ability to attract investors effectively stands as the decisive factor that separates the success of your pioneering research
Sangamo Therapeutics has announced another wave of job losses and a plan to license out two lead clinical programmes as it tries to reinvent itself as a neurology-focused
Biotech investment may be somewhat in the doldrums at the moment, but the sector continues to see a steady stream of deals – particularly in the venture capital category –
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.